PROJECT SUMMARY
Project 3: Defining and defeating the mechanisms of outer membrane biogenesis in Gram-negative bacteria
Gram-negative bacteria are surrounded by an outer membrane (OM) composed of lipopolysaccharide (LPS) that
creates a formidable permeability barrier preventing the uptake of many drugs. The spread of acquired antibiotic
resistance mechanisms among Gram-negative bacteria combined with the intrinsic resistance conferred by the
OM has severely limited treatment options for infections with these organisms. Therefore, the development of
new antibiotics effective against Gram-negative bacteria is an urgent medical need. To enable the discovery of
these treatments, our CARBIRU team will uncover new vulnerabilities and targets required for OM assembly
using E. coli as a model organism. Our approach will be three-pronged. Aim 1 will focus on the essential Bam
machine that assembles beta-barrel proteins in the OM. We have purified and characterized different states of
the six-member complex, including an intermediate state engaged with a substrate. To determine which states
of the machine are the most effective to target with drugs that disrupt the OM permeability barrier, we will use
our nanobody screening platform to identify nanobodies that selectively bind purified complexes locked in
different conformations. The ability of the nanobodies to engage with surface exposed Bam epitopes on cells
and promote cell killing or permeability will then be assessed. Structures of the nanobody-bound complexes will
also be determined using cryo-EM methods that successfully elucidated the structure of the stalled Bam
machine. The results will provide insights into the mechanism of Bam function and define susceptible domains
within the machine. The second aim will investigate the role of the essential membrane protein YejM in regulating
LPS synthesis. LpxC is the committed step in the pathway, and it has long been known to be subjected to
proteolysis by the FtsH protease. However, it has remained unclear how LpxC proteolysis is regulated to
coordinate LPS synthesis with OM assembly. We will test the hypothesis that YejM is responsible for this
coordination and elucidate the regulatory mechanism. The results will teach us how the important drug target
LpxC is regulated in enterobacterial pathogens and identify new ways to disrupt LPS synthesis for antibiotic
development. Finally, we will investigate the mechanism by which undecaprenyl-phosphate (Und-P) is recycled.
Und-P is the lipid carrier used for the synthesis of most cell surface polysaccharides, including peptidoglycan
and the O-antigen of LPS. Our genetic and bioinformatic analyses identified two conserved protein families as
candidates for the long-sought flippases that recycle Und-P. We will investigate their role in Und-P transport and
how their inactivation affects OM assembly and OM modifications that promote antibiotic resistance. Because
Und-P recycling is central to cell envelope assembly, the results will define an attractive new class of targets for
antibiotics or antibiotic potentiators. Overall, our results with these conserved systems will be highly relevant to
the development of novel treatments for infections with a broad-spectrum of Gram-negative pathogens.
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
047006379
UEI
JDLVAVGYJQ21
Project Start Date
07-September-2022
Project End Date
30-June-2026
Budget Start Date
01-July-2024
Budget End Date
30-June-2025
Project Funding Information for 2024
Total Funding
$876,838
Direct Costs
$533,389
Indirect Costs
$343,449
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$876,838
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U19AI158028-03 8150
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U19AI158028-03 8150
Patents
No Patents information available for 5U19AI158028-03 8150
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U19AI158028-03 8150
Clinical Studies
No Clinical Studies information available for 5U19AI158028-03 8150
News and More
Related News Releases
No news release information available for 5U19AI158028-03 8150
History
No Historical information available for 5U19AI158028-03 8150
Similar Projects
No Similar Projects information available for 5U19AI158028-03 8150